1
|
Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J, Hill EB, Yadav M, Bolon BN, Lee RJ, Lee LJ, Croce CM, Garzon R, Caligiuri MA, Bloomfield CD, Marcucci G. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia 2015; 29:2143-53. [PMID: 26055302 PMCID: PMC4633325 DOI: 10.1038/leu.2015.139] [Citation(s) in RCA: 89] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Revised: 04/15/2015] [Accepted: 05/06/2015] [Indexed: 12/31/2022]
Abstract
Current treatments for acute myeloid leukemia (AML) are designed to target rapidly dividing blast populations with limited success in eradicating the functionally distinct leukemia stem cell (LSC) population, which is postulated to be responsible for disease resistance and relapse. We have previously reported high miR-126 expression levels to be associated with a LSC-gene expression profile. Therefore, we hypothesized that miR-126 contributes to “stemness” and is a viable target for eliminating the LSC in AML. Here we first validate the clinical relevance of miR-126 expression in AML by showing that higher expression of this microRNA (miR) is associated with worse outcome in a large cohort of older (≥60 years) cytogenetically normal AML patients treated with conventional chemotherapy. We then show that miR-126 overexpression characterizes AML LSC-enriched cell subpopulations and contributes to LSC long-term maintenance and self-renewal. Finally, we demonstrate the feasibility of therapeutic targeting of miR-126 in LSCs with novel targeting nanoparticles (NP) containing antagomiR-126 resulting in in vivo reduction of LSCs likely by depletion of the quiescent cell subpopulation. Our findings suggest that by targeting a single miR, i.e., miR-126, it is possible to interfere with LSC activity, thereby opening potentially novel therapeutic approaches to treat AML patients.
Collapse
Affiliation(s)
- A M Dorrance
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - P Neviani
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - G J Ferenchak
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - X Huang
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymeric Biomedical Devices, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Department of Biomedical Informatics, Ohio State University, Columbus, OH, USA
| | - D Nicolet
- Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, MN, USA
| | - K S Maharry
- Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, MN, USA
| | - H G Ozer
- Department of Biomedical Informatics, Ohio State University, Columbus, OH, USA
| | - P Hoellarbauer
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - J Khalife
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - E B Hill
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - M Yadav
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - B N Bolon
- Comparative Pathology and Mouse Phenotyping Shared Resource, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - R J Lee
- Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymeric Biomedical Devices, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Department of Biomedical Informatics, Ohio State University, Columbus, OH, USA
| | - L J Lee
- Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymeric Biomedical Devices, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Department of Biomedical Informatics, Ohio State University, Columbus, OH, USA
| | - C M Croce
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
| | - R Garzon
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
| | - M A Caligiuri
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - C D Bloomfield
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.,Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - G Marcucci
- Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
| |
Collapse
|
2
|
Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia 2015; 29:1981-92. [PMID: 25971362 DOI: 10.1038/leu.2015.106] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Revised: 02/17/2015] [Accepted: 04/09/2015] [Indexed: 12/20/2022]
Abstract
High levels of microRNA-155 (miR-155) are associated with poor outcome in acute myeloid leukemia (AML). In AML, miR-155 is regulated by NF-κB, the activity of which is, in part, controlled by the NEDD8-dependent ubiquitin ligases. We demonstrate that MLN4924, an inhibitor of NEDD8-activating enzyme presently being evaluated in clinical trials, decreases binding of NF-κB to the miR-155 promoter and downregulates miR-155 in AML cells. This results in the upregulation of the miR-155 targets SHIP1, an inhibitor of the PI3K/Akt pathway, and PU.1, a transcription factor important for myeloid differentiation, leading to monocytic differentiation and apoptosis. Consistent with these results, overexpression of miR-155 diminishes MLN4924-induced antileukemic effects. In vivo, MLN4924 reduces miR-155 expression and prolongs the survival of mice engrafted with leukemic cells. Our study demonstrates the potential of miR-155 as a novel therapeutic target in AML via pharmacologic interference with NF-κB-dependent regulatory mechanisms. We show the targeting of this oncogenic microRNA with MLN4924, a compound presently being evaluated in clinical trials in AML. As high miR-155 levels have been consistently associated with aggressive clinical phenotypes, our work opens new avenues for microRNA-targeting therapeutic approaches to leukemia and cancer patients.
Collapse
Affiliation(s)
- J Khalife
- Program of Molecular, Cellular, and Developmental Biology, The Ohio State University, Columbus, OH, USA
| | - H S Radomska
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - R Santhanam
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - X Huang
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - P Neviani
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - J Saultz
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - H Wang
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - Y-Z Wu
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - H Alachkar
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - M Anghelina
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - A Dorrance
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - J Curfman
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - C D Bloomfield
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - B C Medeiros
- Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | - D Perrotti
- Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - L J Lee
- William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.,Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymeric Biomedical Devices, The Ohio State University, Columbus, OH, USA
| | - R J Lee
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.,Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA
| | - M A Caligiuri
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - F Pichiorri
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - C M Croce
- Department of Molecular Virology, Immunology and Cancer Genetics, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - R Garzon
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - M L Guzman
- Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA
| | - J H Mendler
- James P. Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, NY, USA
| | - G Marcucci
- Division of Hematopoietic Stem Cell & Leukemia Research, Department of Hematology & HCT, Gehr Family Center for Leukemia, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
| |
Collapse
|
3
|
Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ, Walker CJ, Hokland P, Roy DC, Caligiuri MA, Marcucci G, Huettner CS, Perrotti D. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia 2013; 27:1996-2005. [PMID: 23670294 DOI: 10.1038/leu.2013.151] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2012] [Revised: 04/16/2013] [Accepted: 05/01/2013] [Indexed: 12/30/2022]
Abstract
The dismal outcome of blast crisis chronic myelogenous leukemia (CML-BC) patients underscores the need for a better understanding of the mechanisms responsible for the development of drug resistance. Altered expression of the anti-apoptoticBcl-xL has been correlated with BCR-ABL leukemogenesis; however, its involvement in the pathogenesis and evolution of CML has not been formally demonstrated yet. Thus, we generated an inducible mouse model in which simultaneous expression of p210-BCR-ABL1 and deletion of bcl-x occurs within hematopoietic stem and progenitor cells. Absence of Bcl-xL did not affect development of the chronic phase-like myeloproliferative disease, but none of the deficient mice progressed to an advanced phenotype, suggesting the importance of Bcl-xL in survival of progressing early progenitor cells. Indeed, pharmacological antagonism of Bcl-xL, with ABT-263, combined with PP242-induced activation of BAD markedly augmented apoptosis of CML-BC cell lines and primary CD34(+) progenitors but not those from healthy donors, regardless of drug resistance induced by bone marrow stromal cell-generated signals. Moreover, studies in which BAD or Bcl-xL expression was molecularly altered strongly support their involvement in ABT-263/PP242-induced apoptosis of CML-BC progenitors. Thus, suppression of the antiapoptotic potential of Bcl-xL together with BAD activation represents an effective pharmacological approach for patients undergoing blastic transformation.
Collapse
Affiliation(s)
- J G Harb
- 1] Human Cancer Genetics Program, Department Molecular Virology Immunology and Medical Genetics, Columbus, OH, USA [2] Blood Center of Wisconsin, Blood Research Institute, Milwaukee, WI, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|